Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

Table 2 Summary of the slopes of CD4+ T-cells recovery (cells/mm³/month) for each mtDNA haplogroup and the relationship between them in HIV-infected patients who started combined antiretroviral therapy

Mt DNA haplogroups	Unadjusted analysis*			Adjusted analysis**
Mt DNA haplogroups	No	Yes	p-value	aAMR (95% CI)	p-value
Clusters or major haplogroups
HV	9.1 (5.5; 14)	10 (6.4; 14.7)	0.288	0.98 (0.86; 1.13)	0.839
U	9.8 (6.2; 14.1)	9.1 (5.1; 13.9)	0.321	0.91 (0.77; 1.08)	0.300
JT	9.8 (6.2; 14)	9.2 (5.6; 13.6)	0.765	1.12 (0.94; 1.33)	0.205
Haplogroups
H	9.1 (5.6; 13.7)	10.2 (6.9; 14.1)	0.075	1.04 (0.91; 1.21)	0.544
J	9.8 (6.2; 14)	8.8 (5.2; 12.2)	0.522	1.07 (0.86; 1.32)	0.537
T	9.6 (6.1; 14)	9.7 (6.8; 14.2)	0.735	1.17 (0.90; 1.51)	0.225

HIV human immunodeficiency virus, aAMR adjusted arithmetic mean ratio, CI confidence interval
Statistical: * Values were expressed as median (cells/mm³/month) (percentile 25; percentile 75). p-values were calculated by Mann–Whitney tests. ** Values were expressed as adjusted arithmetic mean ratio (aAMR) and 95% of confidence interval (95% CI) of the slopes of CD4+ T-cells recovery (cells/mm³/month). p-values were calculated by Generalized Linear Models test with a normal distribution (log-link). These regressions were adjusted by the most important clinical and epidemiological characteristics (gender, age, length of HIV-infection, baseline CD4+ cells/mm³, HIV transmission route related to IDU, hepatitis C and hepatitis B coinfection, and type of cART regimen)

ISSN: 1479-5876